Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Retained Earnings (2016 - 2026)

Ironwood Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at -$1.1 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 214.84% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.1 million, a 214.84% decrease, with the full-year FY2025 number at -$1.1 million, down 214.84% from a year prior.
  • Retained Earnings hit -$1.1 million in Q4 2025 for Ironwood Pharmaceuticals, up from -$1.7 billion in the prior quarter.
  • Over the last five years, Retained Earnings for IRWD hit a ceiling of $923000.0 in Q4 2024 and a floor of -$1.7 billion in Q2 2023.
  • Historically, Retained Earnings has averaged -$914.2 million across 5 years, with a median of -$885.1 million in 2021.
  • Biggest five-year swings in Retained Earnings: skyrocketed 100.05% in 2024 and later tumbled 331.06% in 2025.
  • Tracing IRWD's Retained Earnings over 5 years: stood at -$937.6 million in 2021, then rose by 25.73% to -$696.4 million in 2022, then tumbled by 143.92% to -$1.7 billion in 2023, then skyrocketed by 100.05% to $923000.0 in 2024, then plummeted by 214.84% to -$1.1 million in 2025.
  • Business Quant data shows Retained Earnings for IRWD at -$1.1 million in Q4 2025, -$1.7 billion in Q3 2025, and -$2.0 million in Q2 2025.